GLP-1 lawsuits reach 4,238 pending cases across two federal dockets
The federal case count for GLP-1 product liability litigation now stands at 4,238 pending actions, a figure that reflects how many lawsuits have been filed, not any finding that the drugs caused harm.
Federal courts are handling 4,238 pending lawsuits over GLP-1 medications across two consolidated dockets, according to the Judicial Panel on Multidistrict Litigation's statistics report dated September 1, 2026 [1]. MDL 3094 accounts for 4,022 of those pending cases, and the newer MDL 3163 accounts for 216 [1].
The two dockets are both assigned to Judge Karen S. Marston in the Eastern District of Pennsylvania [1]. MDL 3094 is titled IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation [1]. MDL 3163 is titled IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, which means it covers a specific eye condition [1].
The same report shows a cumulative filing figure for each docket. MDL 3094 lists 4,056 actions filed in total against 4,022 now pending, a difference of 34 [1]. MDL 3163 lists 216 actions filed and 216 pending, so every case filed in that docket is still counted as pending [1]. The report gives no explanation for the 34-case gap in MDL 3094, and it does not say whether those cases were dismissed, remanded or moved elsewhere [1].
By size, the GLP-1 docket sits near the top of the panel's list. Eleven other MDLs in the September 1 report show more pending actions, including the talcum powder litigation at 69,250 pending, the Depo-Provera litigation at 6,403 and the Paragard IUD litigation at 4,185 [1]. The separate NAION docket, at 216 pending, is far smaller [1].
The report is a count of court dockets. It does not name the manufacturers or the specific GLP-1 medicines involved, does not describe the injuries alleged in MDL 3094 beyond the docket title, and does not include trial dates, rulings or settlement terms for either docket [1]. Those details have not been disclosed in this report.
Why it matters for patients
A pending case count measures how much litigation is moving through federal court. It is not a safety finding. The September 1 report lists lawsuits and assigns them to a judge; it contains no conclusion that any GLP-1 medication caused the injuries described in the case titles, and it includes no action by the Food and Drug Administration or any other regulator [1].
The practical effect of an MDL is procedural: cases filed in many courts are gathered before one judge for pretrial work such as discovery and motions [1]. Being part of MDL 3094 or MDL 3163 does not, by itself, show that a claim has been reviewed, settled or decided [1].
The report also gives only a single snapshot. It does not compare this month's totals with the previous month, so it does not show whether new filings are speeding up or slowing down [1].
What happens next
The panel publishes updated counts as cases move through the two dockets [1]. The next figures will show whether the pending totals rise or fall, but no trial date, hearing date or ruling in either docket appears in the September 1 report, so the timing of major decisions has not been disclosed [1]. Whether the two dockets eventually combine, settle or go to trial is also not addressed [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.